Frontlight ResearchEarly access
Taking peopleNo phase
Testing the marker miR371 in testicular germ cell cancer
Studies how well miR371 tracks disease in testicular cancer.
Key facts
- Who runs it
- Haukeland University Hospital
- Where
- Norway and Sweden6 sites in 2 countriesChoose a country to see its sites
- Trial code
- Registry title
- MicroRNA as Markers in Testicular Cancer
- Status
- Recruiting
- People taking part
- 350 people, planned
- Started
- 31 Dec 2016
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- Biomarker analysis
- Record updated
- 8 August 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with suspected or diagnosed testicular germ cell cancer. It tests a blood marker, miR371, to follow the disease.
- Age
- 18 to 70 years
- Sex
- Men only
- Disease stage
- Suspected testicular cancer referred for surgery to remove the testicle (orchiectomy), or diagnosed testicular germ cell cancer. Conditions listed include stage I to IV and relapsed disease.
Main reasons for not taking part
- Another cancer now or in the past, other than testicular cancer
- Other diseases or conditions that make it hard to receive information and take part in follow-up
- Not able to receive information and give consent
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients with suspected testicular cancer, referred to orchiectomy
- Patients diagnosed with testicular germ cell cancer
- Age 18-70 years of age
- Must be able receive information and to consent
Who cannot take part
- Other prior or concomitant malignancy (other than testicular cancer)
- Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective of this study is establish the performance of miR371 in management of testicular cancer
Treatments tested
- Biomarker analysis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours
- Plain-language title
- Testing the marker miR371 in testicular germ cell cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT04914026, who can take part
- Record updated
- 8 August 2022